Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
Executive Summary
Advocates and drug developers continue to call for an Orphan Drug Act renovation – not to add more years of marketing exclusivity, but to consider allowing easier and cheaper development programs.
You may also be interested in...
Woodcock Says Blowing Up Orphan Drug Act Not Advisable In Current Climate
FDA appears just as nervous as the National Organization for Rare Disorders about what Congress would do if asked to tweak the Orphan Drug Act.
Woodcock Says Blowing Up Orphan Drug Act Not Advisable In Current Climate
FDA appears just as nervous as the National Organization for Rare Disorders about what Congress would do if asked to tweak the Orphan Drug Act.
PDUFA Commitment Letter Formalizes REMS Standardization Schedule
Among other timetables set as part of the broad deal with industry, FDA will host meetings and issue guidances to assess and minimize the burden of REMS on the practitioners and patients.